Representing the largest randomized controlled trial of pharmacogenomic (PGx) testing in mental health, the PRIME Care Clinical Trial measured the impact of GeneSight test results on medication selection and outcomes among 1,944 veterans at 22 VA locations throughout the U.S.
The study, published in the Journal of the American Medical Association (JAMA), demonstrated statistical significance for its co-primary endpoints.
When clinicians did NOT have access to GeneSight test results, their patients were approximately two times more likely to be prescribed medications with significant gene-drug interactions compared to when clinicians had access to GeneSight.
When prescribing decisions could be informed by GeneSight, patients experienced a 28% greater likelihood of achieving depression remission over 24 weeks compared to treatment as usual.
Findings show the considerable influence testing can have on clinician prescribing decisions and consequent patient outcomes. Significant improvement in remission rate in the GeneSight arm is notable, especially given that 58% of patients were diagnosed with PTSD and 30% with treatment refractory depression, conditions that can make achieving remission even more difficult.
Learn more about GeneSight
1. Oslin DW, et al. JAMA. 2022;328(2):151-161.